The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib

Abstract Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), effectively targets most single ALK mutations in ALK-positive non-small cell lung cancer (NSCLC), while acquired resistance remains a major clinical challenge. In this study, we identified a novel ALK K1150dup mutation in a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mai Nagasaka, Francesco Facchinetti, Ludovic Bigot, Floriane Brayé, Matthew R. Groves, Juvenal Yosa, Anthonie van der Wekken, Mihaela Aldea, Benjamin Besse, David Planchard, Charles Naltet, Ryohei Katayama, Ken André Olaussen, Yohann Loriot, Luc Friboulet
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2026-05-01
Colecção:	npj Precision Oncology
Acesso em linha:	https://doi.org/10.1038/s41698-026-01477-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!